Metformin for Prediabetes After 45: What the Evidence Actually Says
Metformin has been the answer to prediabetes for so long that the question has stopped being asked. That is a shame, because the evidence behind it is unusually specific about who it helps — and a 45-year-old with a borderline A1c is not always that person.
This page is about metformin as a diabetes-prevention drug: the trial that established it, the subgroups where it worked, and where it now sits next to the GLP-1 medications that have overtaken it on effect size. The tirzepatide prediabetes page makes the case from the other side.
The Diabetes Prevention Program
The DPP randomized 3,234 American adults with prediabetes and overweight to one of three arms: intensive lifestyle change, metformin, or placebo. Over an average of 2.8 years, lifestyle intervention reduced progression to type 2 diabetes by 58%. Metformin reduced it by 31%. The result was published in 2002 and has been the foundation of every prediabetes guideline since.
The follow-up study, DPPOS, tracked the same people for more than fifteen years. Metformin's protection persisted — an 18% reduction over the long term — and the drug proved safe across that whole span. Few medications have that kind of record.
Two things in the fine print matter more than the headline.
Lifestyle beat metformin, comfortably. The intensive lifestyle arm — weight loss of around 7%, regular exercise, real coaching — did almost twice as well. Metformin is not a substitute for that. It is what you add when that is not enough, or not possible.
Metformin worked best in specific people. In the DPP, the benefit was concentrated in participants under 60, those with a BMI of 35 or more, and women with a history of gestational diabetes — where the reduction was around 50%, matching lifestyle. In older, leaner participants, the effect was small. The guideline bodies took that seriously: the ADA's recommendation for metformin in prediabetes still names those same groups.
What that means at 45 and beyond
Read the DPP subgroups honestly and a pattern appears. Metformin for prediabetes is strongest in the younger, heavier patient and in the woman whose diabetes risk was flagged in pregnancy. It is weakest in exactly the person who tends to ask us about it — over 60, moderately overweight, A1c just across the line.
That does not make it useless in that patient. It makes it a modest intervention with a modest effect, chosen for its safety, its cost and its lightness rather than its power. For someone who wants the least drug that does something, metformin remains that drug.
For someone whose weight is the main problem, whose fasting insulin has been climbing for years, or whose A1c is moving in the wrong direction despite effort, the honest comparison is with a GLP-1 medication — and on effect size it is not close. Tirzepatide reduced progression by 94% over three years in SURMOUNT-1; metformin by 31% over three in the DPP. They are different tools for different situations, and we prescribe both.
The mechanism, briefly
Metformin reduces the liver's glucose output and improves how muscle responds to insulin. It does not stimulate insulin release, which is why it does not cause hypoglycemia on its own and why it has been safe enough to use for sixty years. It produces a small amount of weight loss — a few percent — as a side effect of appetite rather than as a designed action.
That mechanism is also why it pairs with a GLP-1 rather than competing with one: the two act in different places. The main metformin page covers that combination.
What we check before, and during
Kidney function, because metformin is cleared by the kidney and the safety rules around it are built on eGFR — see metformin and kidney function. B12, because long-term metformin lowers it and the symptoms of deficiency are easy to mistake for aging. And the metabolic picture itself: A1c, fasting glucose and fasting insulin at baseline, then on a schedule, so that "it's working" is a number rather than a feeling.
We are not treating a lab value for its own sake. We are treating a trajectory, and the point of measuring is to know whether the trajectory has changed.
Frequently asked questions
In the Diabetes Prevention Program it reduced progression by 31% over about three years, and by 18% over fifteen. Lifestyle intervention did better, at 58%.
People under 60, those with a BMI of 35 or more, and women with a history of gestational diabetes — the groups the DPP identified and the ADA still names.
On effect size, tirzepatide's 94% reduction over three years is far larger than metformin's 31%. Metformin is lighter, cheaper and has a sixty-year safety record. Which is right depends on weight, trajectory and preference.
A little — a few percent — as a side effect. It is not a weight-loss medication and should not be chosen as one.
Yes; prediabetes is an accepted use, off-label in the US, supported by the ADA's guidance and decades of evidence.
Mostly gastrointestinal, mostly early, often reduced by the extended-release formulation — see ER vs IR. B12 lowering with long-term use is the one to monitor.
Where this fits in your plan
A baseline panel with fasting insulin alongside glucose tells us where on the trajectory you are. From there, the Metformin page covers how it is used here, and the tirzepatide prediabetes page the alternative.
We measure first. Then we act.
References
- Diabetes Prevention Program Research Group. Reduction in the incidence of type 2 diabetes with lifestyle intervention or metformin. NEJM 2002;346:393–403.
- Diabetes Prevention Program Research Group. Long-term effects of metformin on diabetes prevention: identification of subgroups that benefited most in the DPP and DPPOS. Diabetes Care 2019;42:601–608.
- Diabetes Prevention Program Research Group. Long-term effects of lifestyle intervention or metformin on diabetes development and microvascular complications over 15-year follow-up (DPPOS). Lancet Diabetes & Endocrinology 2015;3:866–875.
- American Diabetes Association. Standards of Care in Diabetes — 2026. Section 3: Prevention or Delay of Diabetes.
- Jastreboff AM et al. Tirzepatide for Obesity Treatment and Diabetes Prevention. NEJM 2024.
How we write and review our content
ACT 2 Health provides clinician-led care. Treatments are available only to eligible patients following clinical evaluation and within applicable regulations. This content is educational and is not medical advice. Individual results vary.
Diagnostic testing does not diagnose or rule out disease on its own and is interpreted by a licensed provider alongside your history and examination.
All medical decisions are made solely by licensed healthcare professionals. Medications are prescribed only when medically necessary. GLP-1 medications are not suitable for everyone. Results may vary.
Care is delivered via telemedicine by healthcare professionals licensed in the state where the patient is located. Services are available only in states where our providers are licensed.